This article is more than 5 years old. Information may no longer be current.
Survey results show retina specialists adopting new treatment
Click Here to Manage Email Alerts
LAS VEGAS — Some U.S. retina specialists now choose Eylea to manage 1 disc area of subfoveal choroidal neovascular membrane, according to a presenter here.
“Over the years, anti-VEGF therapy has certainly become the predominant treatment choice, and with this last year in the United States, 10.8% of respondents use Eylea [aflibercept, Regeneron] for this particular scenario,” J. Michael Jumper, MD, said at the American Society of Retina Specialists meeting, reporting trends identified from results of the 2012 ASRS Preferences and Trends Survey of retina specialists.
J. Michael Jumper
A geographic difference identified among responses was that the U.S. protocol for giving intravitreal injections calls for patients and clinicians to refrain from speaking, whereas protocols in other countries more frequently call for both parties to wear masks.
In a surgical survey scenario, more surgeons indicated that they choose to peel internal limiting membrane for routine epiretinal membrane surgery.
“This [percentage] has gone up over the years such that in 2012 about 45% of respondents overall said that they would do that 76% to 100% of the time,” Jumper said.
Disclosure: Jumper has no relevant financial disclosures.